Summit Therapeutics appoints Kenneth A. Clark, partner at WSGR, to Board; Erdtmann resigns

Summit Therapeutics Inc.

Kenneth A. Clark elected to board of directors, effective October 7, 2021.
Clark is a partner at Wilson Sonsini Goodrich & Rosati, specializing in biotech strategic M&A and financing.
Ramses Erdtmann resigned to pursue other opportunities; resignation not due to any disagreement with the company.
Clark appointed to Audit, Compensation, and Nominating and Corporate Governance Committees.
Received grant of stock options under Summit's non-employee director compensation policy.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kenneth A. Clark

Director

SMMT · Summit Therapeutics Inc.

Effective: 2021-10-07
Filed: October 8, 2021, 7:59 PM ET

Effective on October 7, 2021, the board of directors (the “Board”) of Summit Therapeutics Inc. (the “Company”) unanimously approved (i) the election of Kenneth A. Clark as a director of the Company and (ii) the appointment of Mr. Clark to serve on each of the Audit, Compensation, and Nominating and Corporate Governance Committees.

Departed

Ramses Erdtmann

Director

SMMT · Summit Therapeutics Inc.

Effective: 2021-10-07
Filed: October 8, 2021, 7:59 PM ET

On October 7, 2021, Ramses Erdtmann resigned from the Board to pursue other professional opportunities.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kenneth A. Clark was elected as Director at Summit Therapeutics Inc..

Action: elected
Role: Director

Exact text from the filing

Effective on October 7, 2021, the board of directors (the “Board”) of Summit Therapeutics Inc. (the “Company”) unanimously approved (i) the election of Kenneth A. Clark as a director of the Company and (ii) the appointment of Mr. Clark to serve on each of the Audit, Compensation, and Nominating and Corporate Governance Committees.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ramses Erdtmann resigned as Director at Summit Therapeutics Inc..

Action: resigned
Role: Director

Exact text from the filing

On October 7, 2021, Ramses Erdtmann resigned from the Board to pursue other professional opportunities.

View on SEC.gov

Summit Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193805-21-001429

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.